Eosinophils (EOSs) are granular leukocytes that have significant roles in many inflammatory and immunoregulatory responses, especially asthma and allergic diseases. We have undertaken a fairly comprehensive proteomic analysis of purified peripheral blood EOSs from normal human donors primarily employing 2-DE with protein spot identification by MALDI-MS. Protein subfractionation methods employed included IEF (Zoom s Fractionator) and subcellular fractionation using differential protein solubilization. We have identified 3141 proteins, which had Mascot expectation scores of 10 À3 or less. Of these 426 were unique and non-redundant of which 231 were novel proteins not previously reported to occur in EOSs. Ingenuity Pathway Analysis showed that some 70% of the non-redundant proteins could be subdivided into categories that are clearly related to currently known EOS biological activities. Cytoskeletal and associated proteins predominated among the proteins identified. Extensive protein posttranslational modifications were evident, many of which have not been previously reported that reflected the dynamic character of the EOS. This data set of eosinophilic proteins will prove valuable in comparative studies of disease versus normal states and for studies of gender differences and polymorphic variation among individuals.
Introduction
Eosinophils (EOS) are pleiotropic multifunctional granulocytic leukocytes that function in diverse inflammatory and immunoregulatory responses (see reviews [1, 2] ). Important pathologies associated with EOSs include asthma, allergy, and parasitic helminth infections [1, 3] . In normal adults, EOSs are produced, differentiated, and matured in the bone marrow, migrate into the peripheral blood, and subsequently target to different tissues including mammary gland, thymus, uterus, lung, and especially the gastrointestinal tract [1] . However, in many inflammatory pathologies EOSs can also be associated with numerous other organs and tissues. EOS trafficking into inflammatory sites involves a number of cytokines, chemokines, growth factors, lipids, as well as four major cationic proteins (EOS peroxidase (EPO), major basic proteins (MBP), EOS cationic protein (ECP), EOS-derived neurotoxin (EDN)) packaged within four types of cytoplasmic granules each with unique morphologies [1, 4] .
Most current established methods of preparing EOSs from peripheral blood utilizing anti-CD16 immunomagnetic beads to remove neutrophils yield a population of cells which is relatively homogenous, typically greater than 98% [5] . However, density gradient centrifugation can further distinguish two populations of EOSs termed ''normodense'' (specific gravity 41.085 g/L) and ''hypodense'' (specific gravity o1.085 g/L) [6] . Hypodense EOSs typically account for 5-10% of the total peripheral blood EOS population in normal adults and represent activated and degranulated cells [7] . Normodense EOSs can be converted to a hypodense form in vitro by a number of different stimuli; e.g. granulocyte-macrophage colony-stimulating factor, interleukin-3, eotaxin, and interleukin-5 [8] . Moreover, in much inflammatory pathology the hypodense population of cells is increased; however, the composition of these hypodense EOSs can differ when compared with in vitro stimulated cells [4, 8, 9] . Therefore, within the hypodense population of EOSs there is indication of further microheterogeneity likely due to differential degranulation depending on the nature of the stimulus employed or the pathology involved. Thus, the molecular basis for all of the observed EOS heterogeneity is not fully established and clearly requires further investigation. A comparative proteome map of EOSs from normal adults would be considerably important toward defining EOS heterogeneity, especially in inflammatory diseases.
It is clear that EOSs play an important role in the etiology of bronchial asthma, which is one of the fastest growing diseases in the Western world. The prevalence of asthma has increased steadily over the last two decades and in 2006 an estimated 16.1 million adults (7.3%418 years) and some 9.4% or 6.8 million children were affected by the disease in the United States [10] . The rapid increase in the incidence of asthma and its resulting consequence on the healthcare system underscores the need for the identification (ID) of new therapeutic targets for the treatment of allergic inflammation. None of the currently available treatments for asthma and allergic diseases are curative. Recently, a number of factors have been proposed which appear to control EOS trafficking, survival and activation in animal models; however, to date, no therapeutic target has been developed which successfully eliminates tissue-activated EOSs in human trials. Furthermore, the dual role of EOSs in pro-inflammation and anti-inflammation has yet to be elucidated fully. Together these findings clearly emphasize the current status of an incomplete understanding of EOS activation and function, and argue for more comprehensive studies of the EOS phenotype.
We hypothesize that an unbiased characterization of a comprehensive set of proteins expressed by EOSs will provide novel insights into the molecular circuitry, signaling pathways, pro-inflammatory mediators, and cytokines that may play a role in the pathogenesis of EOS inflammation. Furthermore, the map will be important in comparative EOS studies of disease or therapeutic treatments. In the present work, we initiated the proteomic characterization of peripheral blood EOSs obtained from healthy, non-allergic donors. Furthermore, in order to decrease the complexity of the cell lysate and maximize the total number of proteins identified in the study, we fractionated the cell lysate into cytoplasmic, membrane, organelle, and nuclear fractions, and resolved the proteins by 2-DE. We report a number of proteins that are unique to EOSs and are associated with EOS effector functions. We posit that the present data will therefore serve as an important reference database for the discovery of markers of activated EOSs and for future studies investigating therapeutic targets for eosinophiliarelated inflammatory diseases.
immediately added to 60 mL of collected blood in two 50 mL polypropylene conical centrifuge tubes and allowed to sediment for 30 min at room temperature (RT). After sedimentation, the leukocyte-containing layer was overlayed onto Histopaque s -1077 (15 mL leukocyte/7.5 mL Histopaque s ) and centrifuged (720 Â g) at RT for 40 min. Following washing at 41C with 20 mM HEPES-1 Â HBSS, granulocytes were recovered by centrifugation (300 Â g for 7 min) and any remaining erythrocytes were lysed with consecutive additions of 5 mL of ice-cold 0.2% NaCl for 30 s followed by 5 mL of 1.8% NaCl. Following the further addition of 20 mL of HBSS, cells were centrifuged at 300 Â g for 7 min at 41C. EOSs were subsequently isolated by negative selection using CD16 1 MicroBeads as instructed by the manufacturer (Miltenyi Biotec). Briefly, CD16
1 cells (essentially neutrophils) were labeled with CD16
1 MicroBeads and the cell suspension was loaded onto a VarioMACS column. The column was placed in the magnetic field of a MACS Separator and the labeled CD16 1 cells were retained on the column. Unlabeled purified EOSs were not retained and were washed out and collected. After removal of the column from the magnetic field, the neutrophil fraction was eluted from the column. EOS purity was consistently monitored by Hansel staining and typically ranged above 98%. The levels of activated EOSs in our preparations ranged between 1-3% as estimated by measurement of the activation marker CD69 [11] .
2-DE sample preparation
Following CD16 1 MicroBead EOS isolation, cells were pelleted at 300 Â g and washed with 30 mL of 1 Â HBSS. After additional centrifugation at 300 Â g for 7 min cells were solubilized for 2-DE in DeStreak rehydration buffer to a protein concentration of 1 mg/mL. If not used immediately for IEF, samples were stored at À801C. EOSs were also subjected to subcellular fractionation using Calbiochem's ProteoExtract s Subcellular Proteome Extraction kit according to the manufacturer's provided protocol. Some samples were also subjected to IEF fractionation using a ZOOM s IEF Fractionator (Invitrogen) following the manufacturer's provided protocol. Ranges of pH collected were 3.0-5.4, 5.4-7.0, and 7.0-10.0. Protein concentrations were established using the RC DC protein assay kit (Bio-Rad). Typically, 10 Â 10 6 cells yielded $500 mg of cell lysate protein.
2-DE
EOS protein samples (200 mg for 11 cm and 350 mg for 18 cm IPG strips) were adjusted to 200 mL (11 cm strips) and 350 mL (18 cm strips) with DeStreak rehydration buffer and buffer/ ampholyte added to give a final concentration of 0.5%. The mixtures were microcentrifuged at 2000 rpm for 2 min. IEF was performed with a multi-sample IPGphor (GE Healthcare). Different pH gradient IPG strips were investigated. Paper wicks were placed over each electrode of the ceramic strip holders and 8 mL of Milli-Q H 2 O was added to the wicks just prior to the addition of sample/DeStreak buffer mixtures. Dry IPG strips were added to each sample mixture with the gel side of the strip facing down and the strips were covered with mineral oil. The strip holders were placed in an IPGphor IEF cell and focused at 201C with the following protocols: for 11 cm IPG strips: 50 V for 11 h (active rehydration), 250 V gradient for 1 h, 500 V gradient for 1 h, 1000 V gradient for 1 h, 8000 V gradient for 2 h, and held at 8000 V for 6 h; for 18 cm IPG strips: 50 V for 11 h, 250 V for 1 h, 500 V for 1 h, 1000 V for 1 h, 8000 V for 2 h, and held at 8000 V for 8 h. IPG strips were then removed and carefully blotted with damp filter paper to remove excess mineral oil. After IEF the strips were equilibrated for 15 min in 4 mL of an equilibration buffer (50 mM Tris-HCl, pH 8.8, containing 6 M urea, 2% SDS, 20% glycerol and 10 mL/mL tri-(2-carboxyethyl) phosphine), followed by 15 min of equilibration with 4 mL of the above buffer containing 25 mg iodoacetamide/mL buffer. Strips were then rinsed with 1 Â Tris-glycine-SDS second dimension electrophoresis running buffer, pH 8.3, and placed in IPG wells of gels with the positive end of the strip toward the left side of the gels. Strips were subsequently overlayed with 0.5% molten agarose. Criterion gels were then placed in a second dimension electrophoresis cell and electrophoresis was conducted using pre-chilled 1 Â electrophoresis running buffer and 150 V for about 2 1 4 h or until the bromophenol blue dye reached the gel bottom. The electrophoresis (101C) protocol for the Protean II gels was as follows: 35 V for 30 min, 50 V for 1 h, 70 V for 1 h, 100 V for 2 h, and 120 V for 12 h or until the dye front reached the bottom of the gel. After the second dimension of electrophoresis the gels were removed from their plates and rinsed with Milli-Q H 2 O prior to staining.
Fluorescent staining of 2-D gels
Gels were fixed, stained, and destained essentially according to the manufacture's (Invitrogen) recommendations. Briefly, gels intended for Pro-Q Diamond staining were fixed in a solution of 50% methanol and 10% acetic acid in double distilled H 2 O overnight with shaking at RT then washed 3 Â in double distilled H 2 O, stained in Pro-Q Diamond stain at RT for 90 min, and destained in a solution of 20% ACN, 50 mM sodium acetate (pH 4.0) in double distilled H 2 O. Gels intended for Sypro Ruby staining were fixed in 10% methanol, 7% acetic acid, in double distilled H 2 O for 2 h at RT. Subsequently, the Sypro Ruby stain was applied overnight at RT followed by destaining (10% ethanol) for 1 h. Some gels underwent both staining processes first with Pro-Q Diamond followed by Sypro Ruby.
Imaging of 2-D gels
Sypro stained gels were imaged at 100 mm resolution with a ProExpress 2-D Proteomic Imaging System (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA) at 460/ 80 nm excitation and 650/150 nm emission wavelengths. Pro-Q Diamond stained gels were imaged with a Fuji FLA-5100 (Fujifilm USA, Valhalla, NY, USA) at 532 nm excitation (laser) and 575 nm longpass emission.
2-D gel image analysis
2-DE gel images were analyzed using Progenesis SameSpots software v2.0 (Nonlinear USA, Durham, NC). This software automatically detects individual protein spots within each image and matches identical protein spots across all images. It also removes noise from measurements of spot volumes using a proprietary algorithm for noise determination and correction. After automatic matching, manual review and adjustments were done to confirm proper spot detection and matching. The intensity of each protein spot was normalized based on the total spot volume of each gel, that is, the spot volume of each spot area was divided by the sum of all spot volumes in the gel. Spots present on less than two gels or with normalized volumes less than 150 were filtered out. Selected spots were robotically picked (Genomic Solutions, Ann Arbor, MI), trypsin digested, and robotically processed (Genomic Solutions) according to the manufacture's recommendations prior to protein ID by MALDI-MS. Tryptic peptide samples were robotically transferred to MALDI-MS target plates. About 1 ml of MALDI matrix solution (CHCA in 50:50 ACN/H 2 O, 5 mg/mL) was also added robotically to the tryptic samples.
Manual gel sample preparation for MS
When many protein spots were to be picked, we employed the Genomic Solutions robotics instrumentation (see Section 2.7). However, for those gels with few spots to be picked we used the following manual procedure. Gel samples were cut into 1 mm size pieces and placed into separate 0.5 mL polypropylene tubes. Ammonium bicarbonate buffer (100 mL of 50 mM, pH 8.0) was added to each tube and the samples were then incubated at 371C for 30 min. After incubation, the buffer was removed and 100 mL of H 2 O was added to each tube. The samples were then incubated again at 371C for 30 min. After incubation, the H 2 O was removed and 100 mL of ACN was added to each tube to dehydrate the gel pieces. The samples were vortexed and after 5 min the ACN was removed. ACN (100 mL) was again added to each of the sample tubes, vortexed, and ACN removed after 5 min. The samples were then placed in a speedvac for 45 min to remove any excess solvent. To a 20 mg vial of lyophilized trypsin (Promega, Madison, WI, USA) was added 2 mL of 25 mM ammonium bicarbonate (pH 8.0). The trypsin solution was then vortexed and added to each sample tube in an amount required to just cover the dried gel (about 10 mL) and the samples were subsequently incubated at 371C for 6 h. After digestion, the samples were removed from the oven and 1 mL of sample solution was spotted directly onto a MALDI target plate and allowed to dry. Subsequently, 1 mL of CHCA matrix solution (50:50 ACN/H 2 O at 5 mg/mL) was applied on the sample spot and allowed to air dry. 
MS

Results
General characterization of the expression data set
A representative 2-DE separation of an EOS whole cell lysate sample is shown in Fig. 1 . The identities of selected nonredundant prominent protein spots are indicated in Table 1 .
Examples of 2-D gels focused over the pH ranges 3-10, 4-7, 5-8, and 6-11 are shown in Fig. 2 . In general, EOS lysates focused reasonably well in the pH range 3-10. To demonstrate gel-to-gel reproducibility five gels were selected and the log of normalized spot volumes from gel 1 was plotted pairwise versus gels 2-5 as shown in Fig. 3 and the Pearson's correlation co-efficient (r 2 ) was calculated. As evident in Fig. 3 , the r 2 values indicated that the 2-DE analyses were reasonably reproducible as conducted (mean7SD 5 0.9184470.01490). The distribution of proteins identified in the various fractions analyzed (subcellular, IEF, and total lysate) is given in Table 2 . Overall, some 3141 proteins from the 2-DE gels were identified by MALDI-TOF/MS from fractions summarized in Table 2 . All of these 3141 protein spots gave protein IDs with an expectation score of o10
À3
. Of these, 426 proteins identified had unique non-redundant SwissProt identifiers and 231 proteins of the 426 were classified as novel proteins not previously reported to be expressed in EOSs (Table 1 ). In general, the fractionation of proteins into the four commercially designated subcellular fractions shown using the ProteoExtract Subcellular Proteome Extraction procedure was quite useful even though some proteins did not distribute authentically; i.e. some proteins distributed correctly according to their known literature localization whereas other proteins did not. For example, many granular proteins (e.g. EPO, ECP, EDN, and MBP) distributed into the cytoskeletal fraction (F4) and most of the actin was in the nuclear fraction (F3). However, in general, the subcellular fractionation method Figure 1 . The proteome map of human peripheral blood EOSs. IEF was conducted in the pH range 3-10 in the first dimension. Major protein spots indicated by arrows are identified in Table 1 . Protein vertical streak was due to galectin-10 insolubility (see Section 4) . A total of 200 mg EOS cell lysate was loaded to the gel. principally proved valuable in reducing protein complexity and increasing low abundance proteins. Figure 4 is a Western blot analysis that shows the distribution of eight randomly selected proteins into the four subcellular fractions (F1-F4) demonstrating in part the effectiveness of the differential fractionation method. Actin was the most prominent protein expressed in EOSs. Because of this fact, we chose to comparatively evaluate actin levels in other leukocytes. Figure 5 shows the comparative distribution of actin and an actin proteolytic cleavage fragment by Western blot analysis of monocyte, neutrophil, and EOS cell lysates.
Ingenuity Pathway Analysis software application
Ingenuity software was applied to the analysis of the EOS expression data set to probe the relevant biological functions of the identified proteins in the data set (Table 1) . Some functions and diseases relevant to the data set are shown in Fig. 6 . Figure 7 shows selected groups of proteins that highlight in more detail the proportion of the identified proteins whose function or impact are particularly relevant to EOS biological activity; namely, immunological disease, inflammatory disease, immune response, immune and lymphatic system development and function, and respiratory disease. Figure 8 gives a histogram of the top canonical pathways associated with the data set. A small p-value indicated a strong association between the data set and the respective pathway. Proteins found in selected EOS disease functional and canonical pathway subsets (Figs. 6 and 8) are listed in Supporting Information Tables S1 and S2 (see  www. proteomics-journal.com).
Discussion
We have identified 3141 proteins, which had Mascot expectation scores of 10 À3 or less. Of these, 426 proteins were unique and non-redundant as identified using the SwissProt protein database. We did not attempt to distinguish differences between males and females nor did we address the extent of observed polymorphic variations between individuals since large numbers of donors would be required. However, further studies are planned to deal with these important issues. Significantly, of the 426 nonredundant proteins 231were novel proteins not previously reported to occur in EOSs. Since only 8% of all proteins excised and analyzed from 2-D gels were among the unique, non-redundant data set (426 proteins), the question arises as to the occurrence and nature of the redundant protein data set (2715 proteins).
There are many explanations for protein redundancy including phosphorylation. We undertook a preliminary assessment of the EOS phosphoproteome using Pro-Q Diamond staining in order to evaluate the contribution of phosphorylation to redundancy (results not shown). The characterization of the EOS phosphoproteome by 2-DE will be separately reported. We found that many EOS proteins were phosphorylated; phosphorylation can be variable at a given site and may be variable as to the number of sites modified all of which contribute to redundancy. In addition, as shown in Fig. 1 This proteomic data set is the largest comprehensive proteomic data set of proteins expressed in normal peripheral blood EOSs reported to date. There have been two reports of comparative proteomic studies. Waschnagg et al. [12] very recently evaluated protein expression differences induced by Birch pollen allergy and identified 97 unique non-redundant EOS proteins of which 90 occur in our list of 426 (Table 1) , which is an excellent agreement. However, a comparative proteomic study of healthy versus atopic dermatitis patients identified 51 differentially expressed proteins of which only three are included in Table 1 [13] .
In this study, we have made some attempt at characterizing the less abundant proteins using ZOOM s pre-fractionation IEF and subcellular fractionation methods. Protein distribution into various fractions using a commercial subcellular fractionation method allowed for the reduction of protein complexity and increased the number of less abundant proteins observed. We found that this fractionation method performed better in reducing protein losses than many other subcellular fractionation methods that can incur appreciable protein loss. Furthermore, the differential solubilization method was amenable to small sample size, gave high protein recoveries, had relatively high throughput, and processing time was fairly short minimizing protein alterations. However, this method is not sufficiently adequate to predict protein localization to specific subcellular compartments.
Characterization of the data set (Table 1) using Ingenuity Pathway Analysis (IPA) revealed a number of interesting features. Especially, worthy of note was that 312 of the 434 (72%) identified non-redundant proteins could be subdivided into categories (Fig. 6 ) which were related to known EOS biological activities directly; e.g. eosinophilia, cell movement, chemotaxis, and activation, or indirectly; e.g. autoimmune diseases. We were able to detect and positively identify many proteins that were relevant to EOS functions involving survival and activation. Recent studies strongly suggest that tissue eosinophilia is more dependent on increased survival in peripheral tissues than increased de novo generation in the bone marrow followed by blood to tissue translocation [14] . Analysis of EOS turnover in vivo revealed their active recruitment to the peritoneal cavity and their prolonged survival there [14] . In this regard, our IPA showed a considerable number of proteins ($125) involved in cell death and survival (Fig. 6) . Most of these proteins have previously not been correlated with EOS survival processes. However, some of these proteins were shown to play roles in other aspects of EOS biology. These observations emphasized the need for more studies to investigate the pro-and anti-apoptotic proteins that regulate EOS survival in end organs to induce or prevent apoptosis in cells depending on whether the need is to protect against helminth parasites or ameliorate EOS-associated diseases.
EOSs are secretory cells that contain large amounts of granules occupying about one-fifth of the cytoplasm [1] . Four major populations of granules have been identified; namely, primary, secondary, small granules, and as well lipid bodies [1] . Our 2-DE studies identified four of the major proteins found in the secondary granules that included, ECP, EDN, EPO, and MBP as well as galectin-10 found in the primary granules. Numerous other proteins have also been reported to occur in the granules [1] . ECP is a secretory ribonuclease associated with host defense against non-phagocytosable pathogens, such as helminthic parasites. It also has antibacterial activity, which is not shared by EDN, another closely related neurotoxic EOS ribonuclease. The mechanism Table 1 into disease and functional categories.
of action of ECP is thought to involve pore formation in target membranes, which is apparently not dependent on its RNAse activity [15] . On the other hand, EDN, which shares 70% homology with ECP has been implicated in antiviral activity against respiratory infections mainly due to its ribonuclease activity [16] . EPO is an EOS haloperoxidase that catalyzes the peroxidative oxidation of halides present in the plasma as well as hydrogen peroxide generated by dismutation of superoxide produced during respiratory burst. This reaction leads to the formation of bactericidal hypohalous acids [17] . MBP was traditionally associated with toxicity against helminthic worms and is at least partly responsible for tissue damage in bronchial mucosa in asthma. The mechanism of its action is believed to be increased membrane permeability through surface charge interactions leading to perturbation of the cell-surface lipid bi-layer. These granule proteins are actively released from activated EOSs and little if any active transcription occurs in mature EOSs. The role of EOSs in the pathophysiology of bacterial and viral infections is still not well elucidated. The second most abundant and notable protein observed by 2-D gel analysis of EOS cell lysates was galectin-10 ( Table 1 , Fig. 1; ID 329) , which occurs mainly in the primary granules of EOSs and for many years was referred to as lysophospholipase or Charcot-Layden crystal protein.
However, new evidence gives strong indication that it belongs to the galectin superfamily of proteins and was designated as galectin-10 by Ackerman et al. [18, 19] . Previously galectin-10 was thought to occur only in EOSs and basophils, but recent work has also identified it in Figure 7 . Subclassification of eosinophilic proteins from Table 1 and Fig. 6 shows a distribution of eosinophilic proteins into diseases and functional categories highly consistent with what is general appreciated regarding eosinophilic biological activity.
human CD4
1 CD25 1 regulatory T cells (CD25 1 Treg cells) where it is thought to function in maintaining immunological self-tolerance by suppressing autoaggressive T cells [20] . Eosinophilic galectin-10 also appears to have lectin-like properties and can bind mannose (in the crystal) [18] . Further investigations are required to elucidate the biological function of this interesting protein. Gel analysis results from both 1-D and 2-D gels, including Western blot analysis using anti-galectin-10, showed that galectin-10 distributed in multiple gel locations. Repeated gel analysis by 1-D SDS-PAGE and Western blotting of EOS cell lysates gave three bands of molecular weights $17, $25, and $75 KDa. Galectin-10 has been reported to be unique in having a propensity to aggregate even in dissociating conditions [21] . Gel analysis by 2-DE was also anomalous with spots at $17 and $25 KDa and pronounced vertical streaking likely due to precipitation at its pI in the first dimension of 2-DE (Fig. 1) . Some dimer formation was also noted (Fig. 1) . Western blot 2-DE analysis of galectin-10 also showed multiple horizontal spots at $17 KDa indicating polymorphism and/or posttranslational modifications. N-terminal acetylation and isoforms for galectin-10 were also identified by 2-DE of CD25 1 Treg-cell lysates and human EOSs [20] . A separate study will be required to fully characterize the various isoforms associated with galectin-10. The 2-D gels showed that EOSs have especially high amounts of actin (Fig. 1, Table 1 ; ID 311), which contributed to the relatively lower abundance of other proteins in the cell lysate samples. Actin cytoskeletal structures and associated proteins likely play important roles in EOS functions, such as signaling (Fig. 8) , cell motility, degranulation, phagocytosis, and activation [22] [23] [24] . Some of the actin was proteolytically processed to smaller Mr forms (Figs. 1 and 5; Table 1 ; ID 275) and some actin was also phosphorylated (Pro-Q Diamond staining not shown). Actin phosphorylation in other cells was previously reported [25, 26] and plays an important role in actin polymerization [27, 28] . Protein MS ID did not distinguish between b-or a-actin since b-and a-actin have virtually identical primary structures. Although non-muscle actin and actin-associated proteins are reported to occur in the nucleus of cells [29] , our previous studies using FITC-phalliodin, anti-a-fodrin [24] , and anti-actin (results not shown) did not indicate the occurrence of nuclear actin in EOSs. However, these results could not rule out the occurrence of very low levels of nuclear actin that could not be detected under the experimental conditions employed or that the actin Ab was not reactive to nuclear actin due to some unique complex formation. Actin levels in EOSs and monocytes were relatively high when compared with neutrophils with considerably more proteolytic processing occurring in monocytes (Fig. 5) . This was also confirmed by 2-DE of cell lysates (results not shown). The observed actin fragment represented the N-terminal domain of actin, since the anti-actin antibody used was raised aganist an N-terminal fragment (actin [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Numerous actin complex-associated proteins were identified; for example, actin-related protein 2/3 complex, gelsolin, vimentin, Rho GDP-dissociation inhibitor, transgelin, moesin, coactosin-like protein, tubulin, cofilin, L-plastin, calreticulin, myosin, F-actin capping (Table 1) into canonical pathways showing a strong emphasis on signaling pathways consistent with the dynamic nature of the EOS.
